A pivotal Phase 3 study evaluating elagolix for the treatment of moderate to severe endometriosis-associated pain was published on 2017-01-01. This publication, detailed in the New England Journal of Medicine, presented findings from the ELARIS EM-II trial, which assessed the safety and efficacy of this oral gonadotropin-releasing hormone (GnRH) antagonist.
Background
Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist. It was investigated for the treatment of endometriosis-associated pain. Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing severe pain and other symptoms. The development of elagolix aimed to provide a therapeutic option for individuals experiencing moderate to severe pain associated with this condition.
Trial design
The published pivotal study, ELARIS EM-II, was a Phase 3 global study. Its primary objective was to evaluate the safety and efficacy of elagolix in subjects diagnosed with moderate to severe endometriosis-associated pain. This trial aimed to provide comprehensive data on the drug's performance in a large patient population, supporting its potential as a therapeutic option for this indication.
What this means
The publication of the pivotal Phase 3 ELARIS EM-II study represents a significant milestone for elagolix in the treatment of moderate to severe endometriosis-associated pain. These findings provide critical clinical evidence regarding the drug's safety and efficacy profile. For clinicians, this publication offers a robust data set to consider when evaluating treatment options for patients suffering from this chronic and often debilitating condition. The results contribute to the growing body of knowledge on oral GnRH antagonists and their role in managing endometriosis.
Source
The information regarding this pivotal study was obtained from PubMed, a database of biomedical literature. The publication, titled "Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist," appeared in the New England Journal of Medicine and was made available on 2017-01-01, accessible via pubmed.ncbi.nlm.nih.gov.